Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01999361 · ClinicalTrials.gov registry record · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
A NA study of Type 1 Diabetes Mellitus, sponsored by Rodolfo Alejandro.
- Recruiting
- Registry status
- NA
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT01999361: Recruiting NA study of Type 1 Diabetes Mellitus, sponsored by Rodolfo Alejandro.
NCT01999361 is a NA study of Type 1 Diabetes Mellitus that is actively recruiting participants, run by Rodolfo Alejandro. The registered enrollment target is 18 participants, below the 172-participant average among 112 other Type 1 Diabetes Mellitus trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01999361, a NA study of Type 1 Diabetes Mellitus, is actively recruiting participants, sponsored by Rodolfo Alejandro.
- RECRUITING
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-center, prospective, open label study in islet transplant recipients after complete islet graft rejection/loss, defined as stimulated c-peptide ≤0.3 ng/mL.
Primary Outcome
Allosensitization after complete islet graft loss after completion of two years of Myfortic® maintenance monotherapy.
Conditions Studied
Interventions
- DRUG Myfortic
Study Locations (1)
Florida
- Diabetes Research Institute - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2009-01 |
| Est. Completion | 2028-12 |
| Phase | NA |
What NCT01999361 shows while recruiting
NCT01999361 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 172-participant average among 112 other Type 1 Diabetes Mellitus trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which Myfortic is the first listed.
NCT01999361 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT01999361 about?
NCT01999361 is a clinical study titled "Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss". This is a single-center, prospective, open label study in islet transplant recipients after complete islet graft rejection/loss, defined as stimulated c-peptide ≤0.3 ng/mL.
What is the current status of trial NCT01999361?
This trial is currently recruiting. It is a NA study. The enrollment target is 18 participants. The study started on 2009-01. Estimated completion is 2028-12.
What conditions does trial NCT01999361 study?
This clinical trial studies the following conditions: Type 1 Diabetes Mellitus.
What interventions are being tested in trial NCT01999361?
The interventions under investigation include: Myfortic (DRUG).
Who is sponsoring clinical trial NCT01999361?
This trial is sponsored by Rodolfo Alejandro, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01999361 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01999361's enrollment target sits among peer trials
18 94th of 112 higher than 18 of 112 other Type 1 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 1 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Accuracy and Precision of the Continuous Glucose Monitoring System 'CareSens Air 3' in Adult Patients With T1DM
RECRUITING · NA
-
Implementing the Spotlight AQ Platform in Adolescent/ Young Adult (16-25 Years Old) Type 1 Diabetics (T1D)
RECRUITING · NA
-
A Hybrid Effectiveness-implementation Trial to Reduce Diabetes Distress in Teenagers
RECRUITING · NA
-
PACTAID App in Adults With Type 1 Diabetes to Help Manage Exercise
RECRUITING · NA
-
GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes
RECRUITING · NA
-
Impact of Metabolic Health on Sperm Epigenetic Marks in Humans
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
- NCT03326310 · 18 participants · Phase 1
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia